Quantum-Si (NASDAQ:QSI – Get Free Report) and VivoSim Labs (NASDAQ:VIVS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Profitability
This table compares Quantum-Si and VivoSim Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
Insider and Institutional Ownership
39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 1.0% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
Quantum-Si currently has a consensus price target of $1.00, suggesting a potential upside of 34.21%. Given Quantum-Si’s stronger consensus rating and higher probable upside, research analysts plainly believe Quantum-Si is more favorable than VivoSim Labs.
Valuation & Earnings
This table compares Quantum-Si and VivoSim Labs”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum-Si | $2.44 million | 66.84 | -$101.34 million | ($0.46) | -1.62 |
| VivoSim Labs | $130,000.00 | 28.97 | -$13.84 million | ($4.47) | -0.05 |
VivoSim Labs has lower revenue, but higher earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Quantum-Si has a beta of 3.25, suggesting that its stock price is 225% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Summary
Quantum-Si beats VivoSim Labs on 12 of the 14 factors compared between the two stocks.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
